Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus

被引:72
作者
Langeveld, JPM
Brennan, FR
Martínez-Torrecuadrada, JL
Jones, TD
Boshuizen, RS
Vela, C
Casal, JI
Kamstrup, S
Dalsgaard, K
Meloen, RH
Bendig, MM
Hamilton, WDO
机构
[1] Inst Anim Sci & Hlth ID Lelystad, NL-8200 AB Lelystad, Netherlands
[2] Axis Genet Plc, Cambridge CB2 4AZ, England
[3] Ingenasa, E-28037 Madrid, Spain
[4] Danish Vet Inst Virus Res, DK-4771 Kalvehave, Denmark
[5] Univ Copenhagen, IMMI Vaccinol Grp, DK-2200 Copenhagen, Denmark
关键词
canine parvovirus; chimaeric plant virus;
D O I
10.1016/S0264-410X(01)00083-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A vaccine based upon a recombinant plant virus (CPMV-PARVO1), displaying a peptide derived from the VP2 capsid protein of canine parvovirus (CPV), has previously been described. To date, studies with the vaccine have utilized viable plant chimaeric particles (CVPs). In this study, CPMV-PARVO1 was inactivated by UV treatment to remove the possibility of replication of the recombinant plant virus in a plant host after manufacture of the vaccine. We show that the inactivated CVP is able to protect dogs from a lethal challenge with CPV following parenteral immunization with the vaccine. Dogs immunized with the inactivated CPMV-PARVO1 in adjuvant displayed no clinical signs of disease and shedding of CPV in faeces was limited following CPV challenge. All immunized dogs elicited high titres of peptide-specific antibody, which neutralized CPV in vitro. Levels of protection, virus shedding and VP2-specific antibody were comparable to those seen in dogs immunized with the same VP2-peptide coupled to keyhole limpet hemocyanin (KLH). Since plant virus-derived vaccines have the potential for cost-effective manufacture and are not known to replicate in mammalian cells, they represent a viable alternative to cut-rent replicating vaccine vectors for development of both human and veterinary vaccines. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3661 / 3670
页数:10
相关论文
共 40 条
[1]   THE EXPRESSION OF HYBRID HIV-TY VIRUS-LIKE PARTICLES IN YEAST [J].
ADAMS, SE ;
DAWSON, KM ;
GULL, K ;
KINGSMAN, SM ;
KINGSMAN, AJ .
NATURE, 1987, 329 (6134) :68-70
[2]   Nasal delivery of vaccines [J].
Almeida, AJ ;
Alpar, HO .
JOURNAL OF DRUG TARGETING, 1996, 3 (06) :455-467
[3]   LIPOPOLYSACCHARIDE, LIPID-A, AND LIPOSOMES CONTAINING LIPID-A AS IMMUNOLOGICAL ADJUVANTS [J].
ALVING, CR .
IMMUNOBIOLOGY, 1993, 187 (3-5) :430-446
[4]   Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed an a plant virus [J].
Brennan, FR ;
Jones, TD ;
Gilleland, LB ;
Bellaby, T ;
Xu, F ;
North, PC ;
Thompson, A ;
Staczek, J ;
Lin, T ;
Johnson, JE ;
Hamilton, WDO ;
Gilleland, HE .
MICROBIOLOGY-SGM, 1999, 145 :211-220
[5]   Immunogenicity of peptides derived from a fibronectin-binding protein of S-aureus expressed on two different plant viruses [J].
Brennan, FR ;
Jones, TD ;
Longstaff, M ;
Chapman, S ;
Bellaby, T ;
Smith, H ;
Xu, F ;
Hamilton, WDO ;
Flock, JI .
VACCINE, 1999, 17 (15-16) :1846-1857
[6]   Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice [J].
Brennan, FR ;
Bellaby, T ;
Helliwell, SM ;
Jones, TD ;
Kamstrup, S ;
Dalsgaard, K ;
Flock, JI ;
Hamilton, WDO .
JOURNAL OF VIROLOGY, 1999, 73 (02) :930-938
[7]   NEUTRALIZATION OF HIV-1 BY SECRETORY IGA INDUCED BY ORAL IMMUNIZATION WITH A NEW MACROMOLECULAR MULTICOMPONENT PEPTIDE VACCINE CANDIDATE [J].
BUKAWA, H ;
SEKIGAWA, KI ;
HAMAJIMA, K ;
FUKUSHIMA, J ;
YAMADA, Y ;
KIYONO, H ;
OKUDA, K .
NATURE MEDICINE, 1995, 1 (07) :681-685
[8]   PEPTIDE VACCINE AGAINST CANINE PARVOVIRUS - IDENTIFICATION OF 2 NEUTRALIZATION SUBSITES IN THE N-TERMINUS OF VP2 AND OPTIMIZATION OF THE AMINO-ACID-SEQUENCE [J].
CASAL, JI ;
LANGEVELD, JPM ;
CORTES, E ;
SCHAAPER, WWM ;
VANDIJK, E ;
VELA, C ;
KAMSTRUP, S ;
MELOEN, RH .
JOURNAL OF VIROLOGY, 1995, 69 (11) :7274-7277
[9]   THE AUTONOMOUSLY REPLICATING PARVOVIRUSES OF VERTEBRATES [J].
COTMORE, SF ;
TATTERSALL, P .
ADVANCES IN VIRUS RESEARCH, 1987, 33 :91-174
[10]  
*COUNC EUR, 1997, EUR PHARM, P795